Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 8 de 8
1.
Ter Arkh ; 86(9): 65-70, 2014.
Article Ru | MEDLINE | ID: mdl-25518508

AIM: To evaluate the efficacy of cytoflavin in the treatment of patients with hypertensive encephalopathy (HE). SUBJECTS AND METHODS: One hundred and forty patients aged 39 to 73 years, diagnosed with HE, were examined and randomized to 2 groups. A study group (n = 74) received cytoflavin in a dose of 2 tablets b.i.d. on days 1 to 25 days inclusive during standard basic therapy. A comparison group (n = 66 persons) had standard basic therapy only. A control group consisted of 30 apparently healthy individuals. The investigators studied the frequency of headache, dizziness, and other complaints and the intensity of cephalalgic syndrome, by using a visual analog scale, the quality of life by the Medical Outcomes Study 36-Item Short-Form Health Survey (MOS SF-36) questionnaire, that of sleep by the subjective sleep characteristics questionnaire elaborated at the Moscow City Somnological Center, the level of asthenia by a subjective asthenia rating scale (Multidimensional Fatigue Inventory (MFI-20), and autonomic status, by applying objective and subjective scales on days 1 and 25 of therapy. RESULTS: The study has shown that cytoflavin used in the above dose for 25 days reduces the frequency and magnitude of complaints of headache, dizziness, "venous" complaints, the degree of autonomic and asthenic disorders, and impairments in the quality of sleep and life in the patients with HE at all disease stages. A stepwise discriminant analysis has indicated that the degree of cephalgic syndrome, and autonomic disorders, and worse sleep quality are the most effective points for using the energy-modifier cytoflavin. CONCLUSION: HE treatment based on the current pathogenetic principles may have a preventive impact on the development of HE or slow down the rate of its progression.


Flavin Mononucleotide/administration & dosage , Headache , Hypertensive Encephalopathy , Inosine Diphosphate/administration & dosage , Neurocirculatory Asthenia , Niacinamide/administration & dosage , Sleep Wake Disorders , Succinates/administration & dosage , Administration, Oral , Adult , Aged , Dose-Response Relationship, Drug , Drug Combinations , Drug Monitoring , Energy Metabolism/drug effects , Female , Headache/diagnosis , Headache/drug therapy , Headache/etiology , Humans , Hypertensive Encephalopathy/complications , Hypertensive Encephalopathy/drug therapy , Hypertensive Encephalopathy/metabolism , Hypertensive Encephalopathy/physiopathology , Hypertensive Encephalopathy/psychology , Male , Middle Aged , Neurocirculatory Asthenia/diagnosis , Neurocirculatory Asthenia/drug therapy , Neurocirculatory Asthenia/etiology , Pain Measurement/methods , Polysomnography , Quality of Life , Severity of Illness Index , Sleep Wake Disorders/diagnosis , Sleep Wake Disorders/drug therapy , Sleep Wake Disorders/etiology , Treatment Outcome , Visual Analog Scale , Vitamin B Complex/administration & dosage
2.
Article Ru | MEDLINE | ID: mdl-25042496

OBJECTIVES: To study correlations between symptoms of hypertensive encephalopathy (HE), structural MRI changes of the brain and affective disorders in the perimenopausal period. MATERIALS AND METHODS: A study included 150 women who have been through natural menopause (group 1) and 100 women in the premenopausal (group 2). Somatic and neurological examination, MRI and psychometric scales for anxiety and depression were used. RESULTS AND CONCLUSIONS: Women with hypertensive encephalopathy in the postmenopausal period had signs of persistent psycho-emotional disorders (higher anxiety, depression of different severity) combined with structural changes in the brain, with their severity increasing with the progression of HE.


Hypertensive Encephalopathy/diagnosis , Postmenopause , Anxiety/complications , Anxiety/diagnosis , Depression/complications , Depression/diagnosis , Female , Humans , Hypertensive Encephalopathy/complications , Hypertensive Encephalopathy/psychology , Middle Aged
4.
Ter Arkh ; 82(12): 10-5, 2010.
Article Ru | MEDLINE | ID: mdl-21516731

AIM: To study the clinical and instrumental characteristics of hypertensive encephalopathy (HE) in early stages, as well as the time course of their changes during long-term antihypertensive therapy (AHT). SUBJECTS AND METHODS: Prior to and after 9-month AHT, 57 patients aged 50-70 years who had uncomplicated grades 1-2 arterial hypertension (AH) with grades I-II HE underwent comprehensive examination comprising the studies of cognitive functions, quality of life (QL), hemorheology, and hemostasis, duplex scanning of great and intracerebral vessels, echocardiography, 24-hour blood pressure monitoring, magnetic resonance imaging. RESULTS: Early-stage HE was characterized by more cerebral complaints, higher rates of hypertensive crises, a greater degree of psychoautonomic syndrome, and worse QL. Focal brain lesions were detected in 74%; left ventricular hypertrophy (LVH) was diagnosed in 61% of cases. All the patients were observed to have cognitive dysfunctions. AHT (amlodipine, lisinopril) produced a good antihypertensive effect and substantial improvements of the patients' cognitive functions, health status, and QL. LVH regression was achieved. CONCLUSION: HE is a clinical manifestation of damage to the brain as the principal target organ in AH and should be therefore kept in mind in estimating the cardiovascular risk. The diagnosis of HE requires the use of tests to evaluate cognitive functions.


Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Hypertensive Encephalopathy/psychology , Quality of Life , Aged , Electrocardiography, Ambulatory , Female , Follow-Up Studies , Humans , Hypertensive Encephalopathy/diagnosis , Hypertensive Encephalopathy/drug therapy , Magnetic Resonance Imaging , Male , Middle Aged , Treatment Outcome , Ultrasonography, Doppler, Transcranial
5.
Psychiatr Prax ; 33(4): 191-3, 2006 May.
Article De | MEDLINE | ID: mdl-16729404

BACKGROUND: Carrying out dialysis against a patient's will poses specific legal and ethical problems. Decisions have to be made under time pressure, there is often an immediate threat to life, the intervention is rather difficult to carry out against a patient's will, and the same dilemma repeats itself continuously within some days. METHOD: We report on a 45-year-old man with moderate dementia due to hypertensive encephalopathy who was involuntarily admitted to a psychiatric hospital by a court order because of his refusal of dialysis. RESULTS: Dialysis could be carried out with moderate coercion in a general hospital and was subsequently accepted by the patient after two treatments. The protest of the psychiatric hospital against the obligation to provide dialysis by coercion was accepted by the superior court some weeks after discharge of the patient, because dialysis is not provided in the psychiatric hospital. DISCUSSION: Though a good outcome could be achieved in this particular case, many questions remain unclear concerning the feasibility of dialysis under coercion in cases of patients with impaired capacity to give informed consent, and the legal responsibility for the realization of court orders.


Coercion , Commitment of Mentally Ill/legislation & jurisprudence , Dementia/psychology , Hypertensive Encephalopathy/psychology , Mental Competency/legislation & jurisprudence , Renal Dialysis/psychology , Treatment Refusal/legislation & jurisprudence , Germany , Hospitals, General/legislation & jurisprudence , Hospitals, Psychiatric/legislation & jurisprudence , Humans , Male , Middle Aged , Referral and Consultation/legislation & jurisprudence
6.
J Affect Disord ; 85(3): 327-32, 2005 Apr.
Article En | MEDLINE | ID: mdl-15780703

BACKGROUND: While patients with depression have been shown to have a greater incidence of vascular risk factors and structural brain changes, any association with dietary co-factors is unclear. METHODS: Forty-seven patients with major depression (mean age = 52.8 years, SD = 12.6) and 21 healthy volunteers (mean age = 54.7 years, SD = 9.1) underwent high-resolution magnetic resonance imaging scanning. T2-weighted films were scored for deep white matter (DWM), periventricular (PV), and subcortical (SC) hyperintensities. RESULTS: There was no difference in lesion severity between patients and control subjects. After controlling for age, vitamin B12 levels were predictive of DWM lesions in patients. DWM and SC lesions were associated with histories of hypertension and diabetes. LIMITATIONS: A relatively small sample of patients were recruited from specialist services and the findings may not represent those observed in larger or community-based cohorts. CONCLUSIONS: In patients with major depression, vitamin B12 levels and histories of hypertension and/or diabetes are predictive of white matter lesions.


Brain/pathology , Depressive Disorder, Major/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Hypertension/epidemiology , Intracranial Arteriosclerosis/epidemiology , Magnetic Resonance Imaging , Vitamin B 12 Deficiency/epidemiology , Adult , Aged , Aged, 80 and over , Cerebral Cortex/pathology , Cerebral Ventricles/pathology , Cohort Studies , Comorbidity , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/pathology , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/psychology , Female , Homocysteine/blood , Humans , Hypertension/diagnosis , Hypertension/psychology , Hypertensive Encephalopathy/diagnosis , Hypertensive Encephalopathy/epidemiology , Hypertensive Encephalopathy/psychology , Intracranial Arteriosclerosis/diagnosis , Intracranial Arteriosclerosis/psychology , Male , Middle Aged , Reference Values , Risk Factors , Statistics as Topic , Vitamin B 12 Deficiency/diagnosis , Vitamin B 12 Deficiency/psychology
7.
Psychol Med ; 30(5): 1017-23, 2000 Sep.
Article En | MEDLINE | ID: mdl-12027039

BACKGROUND: Previous longitudinal studies of the association between depression and cognitive dysfunction have had relatively short follow-up periods. This report presents a long-term study of the association between baseline syndromal depression and cognitive outcome measured 9 to 12 years later. METHODS: Self-CARE (D) depression, cognitive function and pre-morbid intelligence were recorded on 1083 subjects on entry to the Medical Research Council trial of treatment of hypertension in older adults in 1983-5. In 1994-5, we aimed to re-interview all survivors to assess cognitive function using the MMSE. We used multivariate analysis to explore whether baseline depression predicted cognitive outcome after this long follow-up period. RESULTS: Baseline depression was crudely associated with poorer cognitive outcome at time 2. However, this long-term prospective association was no longer apparent after adjusting for baseline cognitive performance, which was associated with baseline depression and robustly predicted cognitive outcome at time 2. We found that gender modified the association between depression and poorer cognitive outcome, so that the association was statistically significant only among men. CONCLUSION: Propensity for depression and failing cognition may have common determinants that still need to be established by future neurobiological investigations in conjunction with further long-term prospective epidemiological research.


Cognition Disorders/diagnosis , Depressive Disorder/diagnosis , Mental Status Schedule/statistics & numerical data , Aged , Cognition Disorders/psychology , Depressive Disorder/psychology , Female , Follow-Up Studies , Humans , Hypertensive Encephalopathy/diagnosis , Hypertensive Encephalopathy/psychology , Intelligence , Male , Personality Inventory/statistics & numerical data , Predictive Value of Tests , Prospective Studies , Psychometrics , Risk Factors
8.
Neurology ; 53(9): 1948-52, 1999 Dec 10.
Article En | MEDLINE | ID: mdl-10599763

OBJECTIVE: To examine whether baseline high blood pressure and antihypertensive treatment predicts cognitive decline in elderly individuals. METHODS: A longitudinal population-based study of elderly individuals (n = 1,373) in Nantes (western France) was undertaken. Individuals 59 to 71 years of age were selected from electoral rolls. High blood pressure at baseline was defined as systolic blood pressure > or =160 mm Hg or diastolic blood pressure > or =95 mm Hg. Cognitive decline was defined as a drop of 4 points or more on the Mini-Mental State Examination between baseline and the 4-year assessment. RESULTS: There is an association between high blood pressure at baseline and cognitive decline at the 4-year assessment (odds ratio, 2.8; 95% CI, 1.6 to 5.0). In participants with high blood pressure, the risk of cognitive decline was 4.3 (95% CI, 2.1 to 8.8) in those without antihypertensive therapy and 1.9 (95% CI, 0.8 to 4.4) in those being treated. In participants with high blood pressure both at baseline and at the 2-year assessment, the risk for untreated participants was 6.0 (95% CI, 2.4 to 15.0) compared with 1.3 (95% CI, 0.3 to 4.9) in treated participants. CONCLUSIONS: High blood pressure was associated with cognitive decline. In individuals with high blood pressure, cognitive decline occurred in a relatively short time period and the risk was highest in untreated hypertensive patients.


Alzheimer Disease/diagnosis , Cognition Disorders/diagnosis , Hypertensive Encephalopathy/diagnosis , Aged , Alzheimer Disease/drug therapy , Alzheimer Disease/psychology , Antihypertensive Agents/administration & dosage , Blood Pressure/drug effects , Cognition Disorders/drug therapy , Cognition Disorders/psychology , Female , Follow-Up Studies , Humans , Hypertensive Encephalopathy/drug therapy , Hypertensive Encephalopathy/psychology , Longitudinal Studies , Male , Middle Aged , Neuropsychological Tests , Odds Ratio , Risk
...